- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 40
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer
- Interventions
- DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Drug
- Lead sponsor
- TesoRx Pharma, LLC
- Industry
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Interventions
- Testosterone cypionate, Nivolumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
- Interventions
- testosterone cypionate, finasteride, placebo injection, placebo pill
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more
- Conditions
- Testosterone Deficiency, Hypogonadism, Male
- Interventions
- Testosterone
- Drug
- Lead sponsor
- Men's Health Boston
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Transgenderism, Reproductive Issues
- Interventions
- Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hypogonadism, Male
- Interventions
- Testosterone Cypionate 200 Mg/ML, Intranasal Testosterone
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
- Interventions
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment, Survey Administration, Testosterone Enanthate, Testosterone Cypionate
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pain, Opioid Use, Androgen Deficiency, Back Pain
- Interventions
- Testosterone Cypionate, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bone Metabolism
- Interventions
- testosterone cypionate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 30 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypogonadism
- Interventions
- Test formulation, Reference formulation
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- DeLand, Florida • Miami, Florida
- Conditions
- Hypogonadism, Male
- Interventions
- Testosterone Cypionate Injection 200 mg/mL
- Drug
- Lead sponsor
- Azurity Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 3 more
- Conditions
- Advanced Cancer
- Interventions
- Testosterone, Placebo
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Hypogonadism, Male
- Interventions
- Testosterone cypionate
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Drug
- Lead sponsor
- TesoRx Pharma, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate, Enzalutamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography
- Procedure · Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hypogonadism
- Interventions
- Testosterone Cypionate
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 75 Years · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico • Houston, Texas
- Conditions
- Castration Resistant Metastatic Prostate Cancer
- Interventions
- Testosterone cypionate, Enzalutamide, Testosterone enanthate
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 6
- States / cities
- San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Recurrent Prostate Cancer
- Interventions
- Testosterone cypionate, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Testosterone Cypionate 100 MG/ML, Placebo
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Klinefelter Syndrome
- Interventions
- Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 31 Days to 90 Days · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado